Skip to main content
Signal8

Vincerx Pharma, Inc. (VINC)

Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers. Established in 2019, Vincerx Pharma is based in Palo Alto, California.

Sector: Biotechnology

Industry: Biotechnology

Vincerx Pharma, Inc. logo

Vincerx Pharma, Inc.

OTC:VINCHealthcare
+0.00%$0.0150
CLOSED
Mkt Cap$79K
EV-
Float5.23M
O/S5.23M
VOL663 sh
$ Vol$10
RVOL0.50×
Inst Own-
SI<0.1%
Net Cash/Sh-
Dilution
Vincerx Pharma, Inc. logoOTC:VINCClosed$0.0150+0.00%
Short interest (FINRA)
0.0%
Oct 30 (18d)

Float 5.23M · Signal8 estimate from ownership filings · Apr 9, 2024

966
Oct 30 (18d)prev 966– 0.0%
1.23
Oct 30 (18d)prev 1.00▲ 23.0%
Borrow (IBKR)

The cost to borrow VINC shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
6.0%
Nov 11 (6d)prev 0.9%▲ 5.1 pts

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 2026966 sh
Oct 15, 2026966 sh
Sep 30, 2026966 sh
Sep 15, 2026966 sh
Aug 31, 2026966 sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume
Nov 11
Latest sessions
DateReported short
Nov 11, 20266.0%
Nov 4, 20260.9%
Nov 2, 2026100.0%
Oct 9, 20260.2%
Sep 17, 2026100.0%
9-session median 2.1%mean 41.3%range 0.2–100.0%

130 calendar days requested; 10 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.

Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.

Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for VINC: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 966 VINC shares were sold short (0.02% of a 5.23M-share float, 1.23 days to cover).